Read More

Harmony Biosciences posts record sales for narcolepsy drug, maps synthetic CBD plans

Harmony Biosciences Holdings (Nasdaq: HRMY) reported record sales for its narcolepsy treatment WAKIX in 2024 and projected stronger revenue for 2025, as the company advances several clinical trials including a non-THC cannabidiol treatment for a rare genetic disorder. The company said Tuesday that WAKIX generated $201.3 million in revenue during …